Nagata Yuki, Bundo Masahiko, Sugiura Saiko, Kamita Masahiro, Ono Masaya, Hattori Kotaro, Yoshida Sumiko, Goto Yu-Ichi, Urakami Katsuya, Niida Shumpei
Medical Genome Center, National Center for Geriatrics and Gerontology, Aichi 474‑8511, Japan.
Department of Experimental Neuroimaging, National Center for Geriatrics and Gerontology, Obu, Aichi 474‑8511, Japan.
Mol Med Rep. 2017 Sep;16(3):3034-3040. doi: 10.3892/mmr.2017.7015. Epub 2017 Jul 15.
Idiopathic normal pressure hydrocephalus (iNPH) is caused by the accumulation of cerebrospinal fluid (CSF) and is characterized by gait disturbance, urinary incontinence, and dementia. iNPH dementia is treatable by shunt operation; however, since the cognitive symptoms of iNPH are often similar to those of other dementias, including Alzheimer's disease (AD), accurate diagnosis of iNPH is difficult. To overcome this problem, the identification of novel diagnostic markers to distinguish iNPH and AD is warranted. Using comparative proteomic analysis of CSF from patients with iNPH and AD, protein tyrosine phosphatase receptor type Q (PTPRQ) was identified as a candidate biomarker protein for discriminating iNPH from AD. ELISA analysis indicated that the PTPRQ concentration in the CSF was significantly higher in patients with iNPH compared with those with AD. In addition, the PTPRQ concentration in the CSF of non‑responders to shunt operation (SNRs) tended to be relatively lower compared with that in the responders. PTPRQ may be a useful biomarker for discriminating between patients with iNPH and AD, and may be a potential companion biomarker to identify SNRs among patients with iNPH. Additional large‑scale analysis may aid in understanding the novel aspects of iNPH.
特发性正常压力脑积水(iNPH)由脑脊液(CSF)积聚引起,其特征为步态障碍、尿失禁和痴呆。iNPH痴呆可通过分流手术治疗;然而,由于iNPH的认知症状通常与包括阿尔茨海默病(AD)在内的其他痴呆症相似,iNPH的准确诊断较为困难。为克服这一问题,有必要鉴定出区分iNPH和AD的新型诊断标志物。通过对iNPH患者和AD患者的脑脊液进行比较蛋白质组学分析,蛋白酪氨酸磷酸酶受体Q型(PTPRQ)被鉴定为区分iNPH和AD的候选生物标志物蛋白。酶联免疫吸附测定(ELISA)分析表明,与AD患者相比,iNPH患者脑脊液中的PTPRQ浓度显著更高。此外,分流手术无反应者(SNR)脑脊液中的PTPRQ浓度与有反应者相比往往相对较低。PTPRQ可能是区分iNPH患者和AD患者的有用生物标志物,并且可能是在iNPH患者中识别SNR的潜在伴随生物标志物。更多大规模分析可能有助于了解iNPH的新情况。